Navigation Links
Mast Therapeutics To Present At The Leerink Swann Rare Disease Roundtable On October 2

SAN DIEGO, Sept. 30, 2013 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the Leerink Swann Rare Disease Roundtable, on Wednesday, October 2nd, 2013 at 3:00 p.m. Eastern time at Le Parker Meridien Hotel in New York City.

Interested parties can access a live audio webcast and slide presentation on the Mast Therapeutics web site at An archived presentation will be available on the web site for 30 days.

About Mast Therapeutics
Mast Therapeutics, Inc. is a publicly traded biopharmaceutical company headquartered in San Diego, California.  The Company is leveraging the MAST (Molecular Adhesion and Sealant Technology) platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop MST-188, its lead product candidate, for serious or life-threatening diseases with significant unmet needs.  MST-188 is a cytoprotective, hemorheologic, anti-inflammatory and anti-thrombotic agent that has potential utility in diseases or conditions characterized by microcirculatory insufficiency (endothelial dysfunction and/or impaired blood flow). 

The Company is enrolling subjects in EPIC, a pivotal phase 3 study of MST-188 in sickle cell disease.  The Company plans to initiate a phase 2 clinical study of MST-188 in acute limb ischemia, a complication of peripheral arterial disease, in early 2014.  More information can be found on the Company's web site at

Mast Therapeutics™ and the corporate logo are trademarks of Mast Therapeutics, Inc.

Forward Looking Statements
Mast Therapeutics cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that are based on the Company's current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements regarding the Company's development plans for MST-188 in acute limb ischemia, including the timing of initiation of the planned phase 2 study.  Among the factors that could cause or contribute to material differences between the Company's actual results and the expectations indicated by the forward-looking statements are risks and uncertainties that include, but are not limited to: delays in the commencement of clinical studies, including as a result of difficulties in obtaining regulatory agency agreement on clinical development plans or clinical study design, opening trial sites, enrolling study subjects and manufacturing sufficient quantities of clinical trial material; the potential for institutional review boards or the FDA or other regulatory agencies to require additional nonclinical or clinical studies prior to initiation of a planned clinical study; and other risks and uncertainties more fully described in the Company's press releases and periodic filings with the Securities and Exchange Commission. The Company's public filings with the Securities and Exchange Commission are available at

You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. Mast Therapeutics does not intend to revise or update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date hereof, except as may be required by law.


SOURCE Mast Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Aratana Therapeutics to Present at BioCenturys NewsMakers in the Biotech Industry Conference
2. Healthpoint Biotherapeutics To Assume Smith & Nephew Name
3. PTC Therapeutics to Present at World Muscle Society Congress
4. MabVax Therapeutics Receives $1,750,000 Small Business Innovation Research Contract Award From The National Cancer Institute To Support Development of Novel Pancreatic Cancer Diagnostic Imaging Agent
5. Chrysalis BioTherapeutics, Inc., Receives $1.5m from the National Cancer Institute to Mitigate Radiotherapy-Induced Brain Tissue Damage
6. Halozyme Therapeutics To Present At The BioCentury Newsmakers In The Biotech Industry Conference
7. Cell Therapeutics Announces Closing of Sale of Convertible Preferred Stock
8. Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity
9. Cell Therapeutics Announces Sale of Convertible Preferred Stock
10. BGI Tech and South Texas Accelerated Research Therapeutics Initiate Collaboration to Advance Unique San Antonio 1000 Cancer Genome Project
11. Breckenridge Completes Acquisition of Certain Cypress Products from Pernix Therapeutics
Post Your Comments:
(Date:10/13/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... Therapy Catapult to advance development of large scale ... immunotherapy. Under the agreement, the Cell Therapy Catapult ... to support advanced clinical trials and eventual commercialization ... --> The Cell Therapy Catapult is a ...
(Date:10/12/2015)... WASHINGTON , Oct. 12, 2015  Former White House ... Press Secretary for the House Narcotics Committee, Robert Weiner ... "Rewriting Drug Policy." The two emphasize that this is now ... Clinton to Jeb Bush , Carly Fiorina ... Sordello cite the newest federal statistics, which they call "a ...
(Date:10/12/2015)... -- MiMedx Group, Inc. (NASDAQ: MDXG ), the leading ... processes to develop and market advanced products and therapies ... Ophthalmic, and the Dental sectors of healthcare, announced today ... 2015, its guidance for the fourth quarter of 2015, ... Senior Secured Credit Facility. --> ...
Breaking Medicine Technology:
(Date:10/13/2015)... Angeles, CA (PRWEB) , ... October 13, 2015 , ... ... To incentivize would-be customers, eMarketing Concepts began a $1 promotion – effectively offering all ... a resounding success, and within weeks the company was flooded with phone calls from ...
(Date:10/13/2015)... ... , ... The Bill Howe Family of Companies is an award winning HVAC ... remediation services. Family-owned and operated for 35 years, they have maintained value, ethics and ... two years in a row from the Union Tribune Reader’s Poll, a Healthiest Company ...
(Date:10/12/2015)... ... 2015 , ... Heroes in Recovery (HIR) is proud to ... Network’s Moments of Change conference in West Palm Beach, Florida. Rob Waggener, CEO ... Dauphinais who exemplify the ideals of the Heroes in Recovery movement. , Noah ...
(Date:10/12/2015)... , ... October 12, 2015 , ... Kevin Costello, winner of the “Check-In and Win ... embarks today for his dream vacation to Hawaii. , “I didn’t believe I could win ... says. “This contest encouraged me to get to the gym and invest in my own ...
(Date:10/12/2015)... ... 12, 2015 , ... The American Society of Clinical Hypnosis ... education and clinical training in a health care discipline. , Many practitioners ... as: losing weight, managing pain, or stopping smoking, etc. Frequently, extravagant statements and ...
Breaking Medicine News(10 mins):